Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080028 · ClinicalTrials.gov registry record · Phase 1
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
A Phase 1 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00080028 is a Phase 1 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 18 participants.
The verdict
NCT00080028, a Phase 1 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.
Interventions
- DRUG Motexafin Gadolinium Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080028
The ClinicalTrials.gov registry entry for NCT00080028 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin Gadolinium Injection is the first listed.
NCT00080028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080028 about?
NCT00080028 is a clinical study titled "Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer". The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.
What is the current status of trial NCT00080028?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants.
What interventions are being tested in trial NCT00080028?
The interventions under investigation include: Motexafin Gadolinium Injection (DRUG).
Who is sponsoring clinical trial NCT00080028?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.